Clinical Research Directory
Browse clinical research sites, groups, and studies.
HOPE-Sepsis: Hemoadsorption Therapy for Sepsis
Sponsor: Shanghai Zhongshan Hospital
Summary
This is a single-center, prospective, single-arm, open-label study that will enroll 30 adult patients with sepsis at Zhongshan Hospital, Fudan University. All participants will receive CA330 hemoadsorption in addition to standard care. Blood samples will be collected at prespecified time points before hemoadsorption (T0), immediately after completion of hemoadsorption (T1), and approximately 24 hours after completion of hemoadsorption (T2) to evaluate changes in IL-6 and other inflammatory biomarkers. TMT-based quantitative proteomics will be performed on plasma samples collected at T0 and T1 to characterize acute treatment-associated molecular changes and explore their relationships with clinical outcomes.
Official title: Proteomic Analysis and Clinical Efficacy Evaluation of Hemoadsorption Therapy in Sepsis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-10-01
Completion Date
2028-03-31
Last Updated
2026-10-08
Healthy Volunteers
No
Conditions
Interventions
Hemoperfusion with CA330 Cytokine Adsorption Column
Patients will receive hemoadsorption therapy using the Cytokine Adsorption Column CA330 (Jafron Biomedical Co., Ltd., Zhuhai, China). During treatment, whole blood passes through an extracorporeal hemoperfusion circuit containing the adsorption cartridge. Circulating inflammatory mediators are removed by adsorption, and the treated blood is returned directly to the patient. Plasma separation is not performed. CRRT may be administered according to routine clinical indications and is not required for study participation. Standard-of-care therapy for sepsis will be provided throughout the study according to the treating team.Each index hemoadsorption session will last approximately 2-4 hours.
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China